AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28254636
Drug: MIRT-AT (MIRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIRT-AT (MIRT plus aquatic therapy)
Trial: 26340977
Drug: Antiplatelet drugs
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet drugs or no antithrombotic treatment (control group)
Trial: 11806295
Drug: Trimetazidine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (80 mg/kg, group 1)
Trial: 11117655
Drug: Ibuprofen liquigel
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen liquigel 200 mg
Trial: 11117655
Drug: Ibuprofen liquigel
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen liquigel 400 mg
Trial: 8623998
Drug: Edrophonium 1
RxNorm normalized name: edrophonium 10 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 1 mg.kg‐1
Trial: 8955970
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no anticholinesterase drug)
Trial: 2821808
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g four times a day)
Trial: 1561531
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of sucralfate (3 times a day) and ranitidine (300 mg after dinnertime)
Trial: 29704513
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg/day
Trial: 27822881
Drug: Sofosbuvir-based treatment
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir-based treatment (sofosbuvir and ribavirin with or without pegylated interferon-α)
Trial: 23139624
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of bisoprolol fumarate 5 mg
Trial: 17921387
Drug: DHA (88
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (88 mg/d) and EPA (22 mg/d)
Trial: 12382292
Drug: Combined spa
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined spa therapy and exercise therapy (Group 1)
Trial: 12382292
Drug: Combined spa
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined spa therapy and exercise therapy (Group 2)
Trial: 12382292
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual activities and standard treatment)
Trial: 10450748
Drug: Filgrastim (G-CSF)
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim (G-CSF) 5 microg/kg/day subcutaneously during and after chemotherapy
Trial: 10450748
Drug: Filgrastim (G-CSF)
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim (G-CSF)
Trial: 31082790
Drug: Low-calorie diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calorie diet plus 40 g/d of oat bran
Trial: 28689306
Drug: Spine-strengthening exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spine-strengthening exercise and posture training (1 hour, three times weekly for 6 months)
Trial: 23511339
Drug: Valsartan 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 0.25 mg/kg per day
Trial: 23511339
Drug: Valsartan 1
RxNorm normalized name: valsartan 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 1 mg/kg per day
Trial: 23511339
Drug: Valsartan 4
RxNorm normalized name: valsartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 4 mg/kg per day
Trial: 17311892
Drug: Constant intravenous
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant intravenous ghrelin infusion at 5 pmol.kg body wt(‐1).min(‐1) for 180 min
Trial: 15502049
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg tramadol
Trial: 11208825
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist plus tamoxifen
Trial: 11208825
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist alone
Trial: 9389419
Drug: Pramlintide 60
RxNorm normalized name: PRAMLINTIDE 600MCG/ML SOLN INJ 5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide 60 microg twice per day
Trial: 18478022
Drug: Citalopram infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram infusion (10 mg)
Trial: 9299654
Drug: Cetirizine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (5 mg)
Trial: 9389015
Drug: Vit-C (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vit-C (0.1 g)
Trial: 1533588
Drug: fosinopril 20
RxNorm normalized name: fosinopril 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fosinopril 20 mg daily
Trial: 3907991
Drug: Sustained-release tablet
RxNorm normalized name: Oratuss 12 Sustained-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release tablet of ketoprofen (200 mg once daily)
Trial: 3907991
Drug: Normal ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal ketoprofen capsules (2 X 50 mg twice daily)
Trial: 3907991
Drug: Sustained-release tablet
RxNorm normalized name: Oratuss 12 Sustained-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release tablet of ketoprofen
Trial: 3907991
Drug: Normal ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal ketoprofen capsules
Trial: 24802413
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor therapy
Trial: 18441389
Drug: Insulin stimulation
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin stimulation for 3 hours
Trial: 16749289
Drug: Aggressive strategy
RxNorm normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive strategy based on early coronary angiography and subsequent revascularization; specific dosage and duration not available.
Trial: 16749289
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (beta-blockers, aspirin, statins); specific dosage and duration not available.
Trial: 10958124
Drug: Placebo analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo analgesic injection (saline IM injection resembling ketorolac 60 mg)
Trial: 10958124
Drug: Placebo oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral analgesia (inactive starch tablet resembling ibuprofen 800 mg)
Trial: 9065610
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg po daily
Trial: 8349838
Drug: 1% w/w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% w/w flurbiprofen toothpaste, used 2 x daily for 12 months
Trial: 3555035
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg of oral ciprofloxacin every 12 hours for two weeks
Trial: 3555035
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg of oral ciprofloxacin every 12 hours for two weeks
Trial: 10152782
Drug: Ciprofloxacin therapy
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin therapy
Trial: 22056152
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) only
Trial: 31899529
Drug: Virtual education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual education via handheld tablet with self-assessment questions, narrated video demonstration, and iterative rounds as needed.
Trial: 20206078
Drug: Nifedipine CR
RxNorm normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine CR 40 mg (NR)
Trial: 20206078
Drug: Benidipine 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benidipine 4 mg (BD)
Trial: 16812979
Drug: Dual renin-angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual renin-angiotensin system blockade (Valsartan added to standard therapy including ACE inhibitor and beta blocker)
Trial: 16812979
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (ACE inhibitor and beta blocker)
Trial: 11730274
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion (2.5 microg/kg/min)
Trial: 7959238
Drug: 0.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/day olsalazine
Trial: 7959238
Drug: 1.0 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g/day olsalazine
Trial: 7959238
Drug: 2.0 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g/day olsalazine
Trial: 7959238
Drug: 2.0 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g/day olsalazine in patients with proctitis
Trial: 7959238
Drug: 2.0 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g/day olsalazine in patients in remission for less than 12 months
Trial: 22071061
Drug: PCEA-only (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA-only (10 mL, at 20 minutes)
Trial: 22071061
Drug: CEI-only (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEI-only (10 mL/h)
Trial: 22071061
Drug: CEI +
RxNorm normalized name: Ceiba pentandra fiber
DrugBank: Ceiba pentandra fiber (DB10411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEI + PCEA (CEI 10 mL/h plus PCEA 10 mL, at 20 minutes)
Trial: 12734084
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy (POC) with 14 mg/m(2) mitoxantrone infusion at the end of tumor excision
Trial: 12734084
Drug: Standard adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard adjuvant treatment (including tamoxifen for postmenopausal women)
Trial: 8995348
Drug: Daflon 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daflon 500 mg (Dios), two tablets/day for two months, in addition to compression therapy
Trial: 8995348
Drug: Daflon 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daflon 500 mg (Dios)
Trial: 8388353
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of Fraxiparin daily (group I)
Trial: 26232172
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium (40 mg/kg every 8 hours for up to 6 doses)
Trial: 26232172
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline placebo (every 8 hours for up to 6 doses)
Trial: 21353271
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination therapy of albendazole, ivermectin, and praziquantel
Trial: 18348383
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug (patch with extract of glycyrrhiza root)
Trial: 21429413
Drug: Bi-level positive
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi-level positive airway pressure (BIPAP) treatment
Trial: 9839760
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg donepezil for 28 days
Trial: 9839760
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg donepezil for 21 days after 7 days of 5 mg donepezil
Trial: 9839760
Drug: Both dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosage regimens (5 mg and 10 mg donepezil)
Trial: 8076659
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (delayed initiation beyond 24 hours and long-term maintenance treatment)
Trial: 8076659
Drug: Immediate aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate aspirin and thrombolytic therapy
Trial: 29987456
Drug: Prednisolone and
RxNorm normalized name: prednisolone and mydriatics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone and mizoribine with warfarin and dipyridamole (group 1)
Trial: 29987456
Drug: Prednisolone and
RxNorm normalized name: prednisolone and mydriatics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone and mizoribine without warfarin and dipyridamole (group 2)
Trial: 28325124
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no obstetric gel)
Trial: 28325124
Drug: Obstetric gel
RxNorm normalized name: chlorhexidine gluconate Topical Cream [Hibitane Obstetric]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obstetric gel (among nulliparous women)
Trial: 28325124
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no obstetric gel, among nulliparous women)
Trial: 23701411
Drug: Levofloxacin 750
RxNorm normalized name: levofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 750 mg single-dose (150 mL)
Trial: 23701411
Drug: Levofloxacin 750
RxNorm normalized name: levofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 750 mg multiple-dose (150 mL once daily for 7 days)
Trial: 23701411
Drug: Levofloxacin 750
RxNorm normalized name: levofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 750 mg regimen
Trial: 19016090
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy for BN (duration not specified)
Trial: 14577344
Drug: DOT (Directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOT (Directly Observed Therapy) during admission
Trial: 14577344
Drug: Non-DOT (self-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-DOT (self-administered therapy) during admission
Trial: 8878167
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion (50 mg/mL, 216 mL/h)
Trial: 8878167
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (9 mg/mL, 3 mL · kg‐1 · h‐1)
Trial: 1613673
Drug: Corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid therapy (intravenous methylprednisolone 2 mg/kg body weight daily for 10 days)
Trial: 1613673
Drug: Control (cotrimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (cotrimoxazole as standard treatment)
Trial: 6439835
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (MFC + F): Induction therapy with mitomycin C, 5-fluorouracil, and cytosine arabinoside followed by intermittent oral administration of 5-fluorouracil for two years.
Trial: 6439835
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (MF'C + F'): Ftorafur administered on the same schedule as regimen A.
Trial: 26169691
Drug: 1064-nm Q-switched
RxNorm normalized name: Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1064-nm Q-switched Nd:YAG laser treatment
Trial: 18468322
Drug: Prosthodontic treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prosthodontic treatments (specific interventions not detailed)
Trial: 18468322
Drug: Denture hygiene
RxNorm normalized name: ALCOHOL,DENATURED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denture hygiene and implants (commercially attractive topics)
Trial: 16631060
Drug: Perioperative sub‐Tenon's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative sub‐Tenon's injection of triamcinolone (30 mg)
Trial: 16631060
Drug: Perioperative sub‐Tenon's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative sub‐Tenon's injection of triamcinolone (20 mg)
Trial: 16631060
Drug: Steroid drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid drops (control group)
Trial: 11704023
Drug: 0.5% aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% aqueous timolol (timolol solution)
Trial: 11704023
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol suspension (timolol gellan)
Trial: 9065721
Drug: Rx 2
RxNorm normalized name: SP RX 228
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rx 2 (high-dose carboplatin (HD-CBDCA) 500 mg/m2/day for 2 days and VP-16 100 mg/m2/day for 3 days)
Trial: 9065721
Drug: Rx 3
RxNorm normalized name: AlleRx 30 Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rx 3 (ifosfamide 1.5 g/m2/day for 3 days followed by carboplatin (CBDCA) 400 mg/m2 on day 4)
Trial: 9065721
Drug: Rx 1
RxNorm normalized name: ALGRX 1207
DrugBank: ALGRX 1207 (DB06482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rx 1 (high-dose cisplatin (HDP) 200 mg/m2 with concurrent sodium thiosulfate (STS) 9.9 g/m2 and etoposide (VP-16) 200 mg/m2/day for 3 days)
Trial: 3318260
Drug: im injection
RxNorm normalized name: filgrastim Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: im injection of hGH
Trial: 3318260
Drug: sc injection
RxNorm normalized name: SC 41930
DrugBank: SC 41930 (DB17101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sc injection of hGH
Trial: 23972320
Drug: Montelukast 4
RxNorm normalized name: montelukast 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 4 mg
Trial: 28947165
Drug: ADL retraining
RxNorm normalized name: Adlyxin
DrugBank: Lixisenatide (DB09265)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ADL retraining during PTA (treatment group)
Trial: 28947165
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) alone (control group)
Trial: 23093054
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (1500 IU) plus fluoxetine (20 mg)
Trial: 23093054
Drug: Fluoxetine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine alone (20 mg)
Trial: 18181241
Drug: D-chlorpheniramine 6
RxNorm normalized name: chlorpheniramine maleate 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-chlorpheniramine 6 mg
Trial: 12749509
Drug: Levofloxacin 750
RxNorm normalized name: levofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 750 mg QD given i.v. and then orally for 7 to 15 days
Trial: 12749509
Drug: Imipenem/cilastatin 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin 500 mg to 1 g i.v. every 6 to 8 hours, followed by oral ciprofloxacin 750 mg every 12 hours for 7 to 15 days
Trial: 26701971
Drug: Single-dose methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose methotrexate (n = 46)
Trial: 26701971
Drug: Two-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose methotrexate (n = 46)
Trial: 14563972
Drug: UK-279,276 (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK-279,276 (dose range, 10 to 120 mg)
Trial: 15220251
Drug: Quinapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (20 mg/day)
Trial: 8546341
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg/day) plus Quinapril (10 mg/day)
Trial: 2035513
Drug: Progression from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progression from normal glucose tolerance to non-insulin-dependent diabetes
Trial: 2035513
Drug: Progression from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progression from impaired glucose tolerance to non-insulin-dependent diabetes
Trial: 2035513
Drug: Overall age-standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall age-standardized incidence of non-insulin-dependent diabetes
Trial: 3909759
Drug: Nifedipine slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine slow-release tablets, 20 mg twice daily
Trial: 29385062
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (1000 mg capsules containing 180 mg eicosapentaenoic acid and 120 mg docosahexaenoic acid, n = 20)
Trial: 26541738
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (0.3 mcg/kg/h for 24 hours)
Trial: 26541738
Drug: Morphine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine infusion (3 mg/h for 24 hours)
Trial: 24797222
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene instructions
Trial: 23198510
Drug: Chlorhexidine gluconate-impregnated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gluconate-impregnated wipes used thrice weekly
Trial: 12669740
Drug: Alendronate therapy
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate therapy